American Association for Cancer Research 2025
The 2025 American Association for Cancer Research (AACR) meeting was held April 25-30, 2025 in Chicago, IL. Click the links below to read about research reported at this meeting that is of interest to people with MBC.
- Cancer Today Magazine: Combining the use of both tumor biopsies and liquid biopsies was better than either type of biopsy alone for identifying people with advanced cancer who have genomic changes and may benefit from targeted therapy
- Cancer Today Magazine: Researchers are studying ways to manage the side effects of immunotherapy drugs, which can be used to treat triple-negative MBC
- OncLive: An immunotherapy combination shows promising safety and benefits in multiple MBC subtypes
- OncLive: Combination therapy consisting of a new targeted therapy, a CDK4/6 inhibitor, and hormone therapy shows promising safety and benefits in hormone receptor–positive, HER2-negative MBC that is resistant to CDK4/6 inhibitors